
- CURE® Genitourinary Cancer 2022 Special Issue
The Past 20 Years Have Been Revolutionary for Kidney Cancer
Once seen as a malignancy resistant to typical treatments such as chemotherapy, metastatic kidney cancer has come a long way in the past 20 years.
Metastatic kidney cancer was once seen as a malignancy that was resistant to typical cancer treatments such as chemotherapy and radiation, leaving patients with limited options and low life expectancy.
However, the past 20 years have brought great advancements and approvals to the space, improving life expectancy and quality of life.
As CURE® continues to
And since 2005, there have been more than a dozen Food and Drug Administration approvals for metastatic kidney cancer, which demonstrates how significant these treatments are for patients.
Along the way, treatments have
Also in this issue, Robert Hollander discusses how
It became a great way of dealing with his situation and continuing his passion while also helping a meaningful cause.
“Everybody who goes through this journey has to find a way of dealing with a difficult situation,” he says. “The winemaking is fun, and having people enjoy it is great too. It’s a small thing, but (I’m) just trying to (make) the best of a challenging situation.”
And don’t forget to HIIT it! For some patients with prostate cancer, treatment with standard therapies may not be the best course, so their doctors recommend active surveillance. However, this period of time can be difficult for many patients, causing psychological distress and affecting their quality of life. But new data demonstrate that high-intensity interval training (HIIT) workouts can improve these patients’ quality of life. CURE® spoke with an expert about
As always, we hope you find these stories to be informative and inspiring. Thank you for reading.
For more news on cancer updates, research and education, don’t forget to